Shares of PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report) were up 2% during trading on Wednesday . The company traded as high as $2.40 and last traded at $2.29. Approximately 60,069 shares changed hands during mid-day trading, an increase of 580% from the average daily volume of 8,831 shares. The stock had previously closed at $2.24.
PharmaCyte Biotech Price Performance
The stock’s 50 day simple moving average is $2.16 and its 200 day simple moving average is $2.18.
PharmaCyte Biotech Company Profile
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.
See Also
- Five stocks we like better than PharmaCyte Biotech
- 3 Stocks to Consider Buying in October
- Autodesk’s Quarterly Results Could Drive It Back to Recent Highs
- P/E Ratio Calculation: How to Assess Stocks
- A Bubble is Brewing in Oracle Stock, and it’s Only Getting Bigger
- Stock Analyst Ratings and Canadian Analyst Ratings
- Danaos Benefits from Increasing Demand in Container Shipping
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
